TRIM32 (Tripartite Motif Containing 32) is a member of the TRIM family of E3 ubiquitin ligases characterized by the N-terminal RING finger, B-box, and coiled-coil (RBCC) domains, followed by a C-terminal SPRY domain. TRIM32 is encoded by the TRIM32 gene located on chromosome 9q33.1 and plays diverse roles in protein ubiquitination, autophagy regulation, and antiviral defense. In the nervous system, TRIM32 is essential for neuronal development, synaptic function, and survival. Mutations in TRIM32 cause limb-girdle muscular dystrophy type 2H (LGMD2H), while dysregulated TRIM32 expression has been implicated in Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis.
TRIM32 possesses the canonical TRIM family architecture:
The SPRY domain of TRIM32 binds to various substrates including titin in muscle cells and PIAS1 in the ubiquitin-proteasome system. TRIM32 can form homodimers through its coiled-coil region, which is required for its E3 ligase activity.
TRIM32 is widely expressed in peripheral tissues including skeletal muscle, heart, and testis, with moderate expression in brain regions including the cerebral cortex, hippocampus, and cerebellum. Within neurons, TRIM32 localizes to both cytoplasmic and nuclear compartments, with enrichment at synaptic terminals. In the mouse brain, TRIM32 expression peaks during postnatal development and remains stable in adult animals.
During brain development, TRIM32 regulates neuronal migration and differentiation through ubiquitination of key signaling molecules. TRIM32-mediated ubiquitination of DLGAP5 (a microtubule-associated protein) influences cytoskeletal dynamics essential for neuronal process extension.
At synapses, TRIM32 modulates glutamate receptor trafficking and signaling. TRIM32 ubiquitinates GRIP1, a scaffolding protein that anchors AMPA receptors to the postsynaptic density, thereby regulating synaptic plasticity and long-term potentiation (LTP).
TRIM32 directly ubiquitinates p62/SQSTM1, a selective autophagy receptor that delivers ubiquitinated cargo to autophagosomes. This interaction links TRIM32 to macroautophagy, a critical process for neuronal homeostasis and clearance of misfolded proteins. TRIM32 also interacts with ATG proteins to coordinate autophagosome formation.
Like other TRIM family members, TRIM32 participates in innate immune responses against viral infections. TRIM32 ubiquitinates and restricts various viruses including HIV-1 and influenza A virus, though the relevance to neurodegenerative disease remains under investigation.
In Alzheimer's disease, TRIM32 expression is altered in affected brain regions. Studies show:
TRIM32 polymorphisms have been associated with late-onset AD risk in some population studies.
In Parkinson's disease, TRIM32 dysregulation affects:
TRIM32 expression is upregulated in ALS spinal cord tissue, where it may:
In Huntington's disease, TRIM32 may:
TRIM32 participates in several key signaling cascades:
| Pathway | Interaction | Effect |
|---|---|---|
| NF-κB Signaling | PIAS1 ubiquitination | Modulates inflammatory responses |
| p53 Pathway | MDM2 interaction | Influences cell cycle and apoptosis |
| JAK/STAT | STAT1 ubiquitination | Regulates cytokine signaling |
| mTORC1 | Autophagy regulation | Controls protein synthesis and degradation |
TRIM32 interacts with numerous cellular proteins:
TRIM32 represents a potential therapeutic target for neurodegenerative diseases:
Currently, no selective TRIM32 modulators are in clinical development. Broader-spectrum E3 ligase modulators may indirectly affect TRIM32 activity.
TRIM32 modulation may be combined with:
Several animal models have been developed to study TRIM32 function:
LGMD2H, caused by TRIM32 mutations, typically presents in childhood with proximal muscle weakness. While primarily a muscular disorder, some patients exhibit mild cognitive involvement.
TRIM32 levels in cerebrospinal fluid may serve as a biomarker for:
Key areas for future research include: